Exelixis Inc (EXEL) concluded trading on Thursday at a closing price of $36.84, with 2.9 million shares of worth about $106.89 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 40.18% during that period and on March 27, 2025 the price saw a loss of about -0.46%. Currently the company’s common shares owned by public are about 281.73M shares, out of which, 271.82M shares are available for trading.
Stock saw a price change of -0.91% in past 5 days and over the past one month there was a price change of -1.84%. Year-to-date (YTD), EXEL shares are showing a performance of 10.63% which increased to 55.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $20.14 but also hit the highest price of $40.02 during that period. The average intraday trading volume for Exelixis Inc shares is 2.65 million. The stock is currently trading -1.96% below its 20-day simple moving average (SMA20), while that difference is up 3.05% for SMA50 and it goes to 21.98% higher than SMA200.
Exelixis Inc (NASDAQ: EXEL) currently have 281.73M outstanding shares and institutions hold larger chunk of about 90.70% of that.
The stock has a current market capitalization of $10.31B and its 3Y-monthly beta is at 0.57. PE ratio of stock for trailing 12 months is 20.78, while it has posted earnings per share of $1.77 in the same period. Its PEG reads 0.97 and has Quick Ratio of 3.58 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EXEL, volatility over the week remained 3.38% while standing at 3.01% over the month.
Stock’s fiscal year EPS is expected to rise by 15.56% while it is estimated to increase by 16.58% in next year. EPS is likely to grow at an annualized rate of 21.53% for next 5-years, compared to annual growth of 11.55% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on February 24, 2025 offering an Equal weight rating for the stock and assigned a target price of $36 to it. Coverage by Morgan Stanley stated Exelixis Inc (EXEL) stock as an Overweight in their note to investors on January 27, 2025, suggesting a price target of $40 for the stock. On January 24, 2025, Oppenheimer Downgrade their recommendations, while on December 20, 2024, BMO Capital Markets Downgrade their ratings for the stock with a price target of $40. Stock get a Neutral rating from BofA Securities on December 17, 2024.
